Please provide your email address to receive an email when new articles are posted on . In 1988, Folberg and colleagues described an atypical granular dystrophy with pathological features of lattice ...

Please provide your email address to receive an email when new articles are posted on . Avellino Lab USA, developer of a genetic test for the mutation that can cause Avellino corneal dystrophy, ...

MENLO PARK, Calif., March 5, 2013 /PRNewswire/ -- Avellino Lab USA, developer of the first genetic test for Avellino Corneal Dystrophy (ACD), today announced the launch of its Menlo Park, ...

The alternative text for this image may have been generated using AI. Twenty milliliters of peripheral blood was drawn from each patient, and genomic DNA was extracted from the leukocytes using a DNA ...

A previously reported 1 Asian pedigree of severe granular dystrophy, where three members were postulated as being homozygotes, was re-examined. At the time of the first report, the pedigree was too ...

MENLO PARK, Calif., Nov. 16, 2015 /PRNewswire/ -- Avellino Lab USA, developer of the first genetic test for corneal dystrophy, today announced that Grace Lytle OD, MS has joined the company as Senior ...

MENLO PARK, Calif., April 24, 2014 /PRNewswire/ -- Avellino Lab USA, developer of the Avellino-GENE Detection System (AGDS(TM)) Test, the first genetic test for Avellino Corneal Dystrophy (ACD), will ...

Avellino, a biotech startup based in Seoul, has developed a pioneering technology that has so far protected over 460 people from losing their sight. Avellino Corneal Dystrophy is a genetic condition ...

Ahead of IPO, ophthalmologic gene diagnosis firm says Korean investors should evaluate company based on merits alone US ophthalmologic gene diagnosis company Avellino Labs is preparing for its initial ...

While there is no treatment for ACD, Avellino Lab USA's AGDS Test is able to detect the presence of the ACD gene mutation allowing the patient to take precautionary steps to potentially postpone the ...